Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Heartland to appeal NAD sweetener decision

This article was originally published in The Tan Sheet

Executive Summary

The maker of xylitol-containing Ideal No Calorie Sweetener says the National Advertising Division's finding against its "More than 99% Natural" claim could deprive consumers of truthful information and "may have dramatic and unintended adverse consequences" for the non-sugar sweetener market. Carmel, Ind.-based Heartland Sweeteners said it will appeal NAD's recommendation to discontinue claims that Ideal is more natural than other no-calorie sweeteners. In a case 1report published Dec. 14, NAD determined that although the synthetic sweetener sucralose makes up less than 1 percent of Ideal's product weight, it accounts for about 80 percent of its sweetness in packet form. Merisant, maker of stevia-based PureVia, brought the challenge to NAD

You may also be interested in...

MSF Wants Faster Deployment Of Ebola Vaccine At ‘Fair’ Price

As stockpiles of Ebola vaccine are being built up around the world, Médecins sans Frontières has said more action is needed to ensure sufficient numbers of vaccinations are available for use in current and future outbreaks. 

Deals Shaping The Medical Industry, December 2019

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced November 2019.

Changing China Is Opening Up For Health Care Entrants

The potential of China’s vast health care products market is alluring. It has proved off-limits to most of the global medtech industry, and is rarely in the early launch strategies of global companies. Government-led initiatives want that to change, as evidenced in the latest Five-Year Plan and the recent Healthy China 2030 report.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts